Pembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Publications
View AllAffiliated Researchers
Institution Info
- Type
- healthcare
- Country
- BE
- Publications
- 1
- Citations
- 5,661
External Links
Identifiers
- ROR
- https://ror.org/038f7y939